ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2011
Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00467961 (Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates.Transfusion · 2016Trial
- Delayed B-cell reconstitution in the bone marrow precedes the development of chronic graft-versus-host disease following pediatric hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Article
- B cells in chronic graft-versus-host disease.Human immunology · 2019Review
- Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!Blood reviews · 2018Review
- NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD.European journal of immunology · 2018Article
- Developing T-cell therapies for lymphoma without receptor engineering.Blood advances · 2017Review
- Developing T-cell therapies for lymphoma without receptor engineering.Hematology. American Society of Hematology. Education Program · 2017Review
- T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.Biomedicines · 2017Review
- Virus-Specific T Cells for the Immunocompromised Patient.Frontiers in immunology · 2017Review
- Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.Bioorganic & medicinal chemistry · 2016Article
- Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies.Advances in hematology · 2016Review
- Allo-reactive T cells for the treatment of hematological malignancies.Molecular oncology · 2015Review
- Immunotherapy for viral and fungal infections.Bone marrow transplantation · 2015Review
- Preventing stem cell transplantation-associated viral infections using T-cell therapy.Immunotherapy · 2015Review
- Radiation exposure from diagnostic procedures following allogeneic stem cell transplantation--how much is acceptable?Hematology (Amsterdam, Netherlands) · 2014Article
- Antiviral T-cell therapy.Immunological reviews · 2014Review
- Accelerating immune reconstitution after hematopoietic stem cell transplantation.Clinical & translational immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
Abstract
We evaluated a photodepletion technique to selectively deplete host-reacting T cells from human leukocyte antigen (HLA)-matched sibling stem cell transplantations with the goal of reducing posttransplantation immunosuppression to improve antimalignancy effects postallografting. Donor lymphocytes were stimulated with irradiated expanded recipient T lymphocytes in an ex vivo mixed lymphocyte reaction. Alloactivated T cells preferentially retaining the photosensitizer 4,5-dibromorhodamine 123 (TH9402) were eliminated by exposure to visible light. Twenty-four patients with hematologic malignancies (16 high risk) conditioned with fludarabine, cyclophosphamide, and totalbody irradiation received a CD34-selected stem cell allograft from an HLA-matched sibling along with 5 × 10(6)/kg selectively depleted donor T cells. Low-dose cyclosporine was used for posttransplantation immunosuppression. Eleven patients survived at a median of 30 months. Probabilities (± SEM) for overall and disease-free survival are 39% ± 12% and 30% ± 12%, respectively, whereas grade III-IV acute graft-versus-host disease (aGVHD) was 13% ± 7%. Six patients relapsed, with a relapse probability of 27% ± 10%. These results suggest that selectively photodepleted allografts in matched sibling transplantations followed by low-dose immunosuppression may protect against severe aGVHD but is associated with delayed immune recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.